Stockscreener 앱 받기
0.4014
6.65%
-0.0286
전일 마감가:
$0.43
열려 있는:
$0.4262
하루 거래량:
7.33M
Relative Volume:
1.26
시가총액:
$135.07M
수익:
$52.29M
순이익/손실:
$-134.84M
주가수익비율:
-0.5352
EPS:
-0.75
순현금흐름:
$-117.11M
1주 성능:
-9.39%
1개월 성능:
-8.98%
6개월 성능:
-16.60%
1년 성능:
-63.51%
1일 변동 폭
$0.4014
$0.4297
1주일 범위
$0.4014
$0.455
52주 변동 폭
$0.3846
$1.40
Sangamo Therapeutics Inc Stock (SGMO) Company Profile
명칭
Sangamo Therapeutics Inc
전화
(510) 970-6000
주소
501 CANAL BLVD., RICHMOND, CA
SGMO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SGMO
Sangamo Therapeutics Inc
|
0.4014 | 144.69M | 52.29M | -134.84M | -117.11M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-07 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-12-13 | 업그레이드 | Truist | Hold → Buy |
| 2024-12-10 | 재확인 | H.C. Wainwright | Buy |
| 2023-11-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-04-28 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-02-27 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2023-01-06 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-06-13 | 재개 | Wedbush | Neutral |
| 2021-05-04 | 개시 | RBC Capital Mkts | Outperform |
| 2021-01-07 | 재개 | Guggenheim | Neutral |
| 2021-01-06 | 개시 | Stifel | Hold |
| 2020-12-16 | 재개 | H.C. Wainwright | Buy |
| 2020-09-08 | 개시 | BofA Securities | Buy |
| 2020-07-07 | 개시 | SunTrust | Buy |
| 2019-08-26 | 개시 | H.C. Wainwright | Buy |
| 2018-11-14 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-11-09 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2018-10-10 | 개시 | Guggenheim | Buy |
| 2018-06-20 | 개시 | BofA/Merrill | Buy |
| 2017-11-15 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2017-06-22 | 재개 | Jefferies | Buy |
| 2016-11-01 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2016-10-19 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2015-12-04 | 개시 | Wells Fargo | Outperform |
| 2015-10-23 | 재개 | Jefferies | Buy |
| 2013-05-03 | 개시 | BioLogic Equity Research | Sell |
| 2011-02-23 | 재확인 | JMP Securities | Mkt Outperform |
| 2010-07-29 | 재확인 | Wedbush | Outperform |
| 2009-10-19 | 개시 | Brean Murray | Sell |
| 2009-10-07 | 재확인 | Leerink Swann | Outperform |
| 2009-08-25 | 재확인 | JMP Securities | Mkt Outperform |
모두보기
Sangamo Therapeutics Inc 주식(SGMO)의 최신 뉴스
Published on: 2026-01-14 05:13:16 - Bộ Nội Vụ
Fabry Disease Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, AVROBIO, 4D Molecular Therapeutics - Barchart.com
Sangamo Therapeutics (SGMO) Shares Stabilize Amid Recent Key Pipeline Update - Finviz
10 Stocks Under $1 That Will Explode - Insider Monkey
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Can Sangamo Therapeutics Inc. stock attract ESG capital inflowsEarnings Growth Report & High Accuracy Buy Signal Tips - Улправда
Is Sangamo Therapeutics Inc. stock oversold or undervaluedWeekly Trend Recap & Daily Growth Stock Investment Tips - Улправда
Why Sangamo Therapeutics Inc. stock remains resilient2025 Momentum Check & Community Shared Stock Ideas - Улправда
Can Sangamo Therapeutics Inc. stock weather global recessionOptions Play & Long-Term Growth Portfolio Plans - Улправда
Surprises Report: How Sangamo Therapeutics Inc. stock compares to industry benchmarksJuly 2025 Technicals & Consistent Profit Trade Alerts - ulpravda.ru
Is Sangamo Therapeutics Inc. stock a contrarian buyMarket Trend Review & Long-Term Growth Stock Strategies - Улправда
Can Sangamo Therapeutics Inc. stock sustain market leadership2025 Volume Leaders & AI Optimized Trade Strategies - Улправда
Inflation Data: How Sangamo Therapeutics Inc. stock compares to industry benchmarks2025 Dividend Review & High Win Rate Trade Tips - Улправда
How Sangamo Therapeutics Inc. stock performs in weak economy2025 Risk Factors & Weekly High Momentum Picks - ulpravda.ru
How resilient is Sangamo Therapeutics Inc. stock in market downturnsJuly 2025 WrapUp & Low Drawdown Trading Techniques - Улправда
Will Sangamo Therapeutics Inc. (GBY) stock benefit from infrastructure billMarket Weekly Review & AI Forecast Swing Trade Picks - Улправда
Is Sangamo Therapeutics Inc. stock attractive for retirement portfoliosFootwear buying guidance for outdoor walking and light jogging focuses on support for wide feet, making it a smart choice when deciding what to buy. - ulpravda.ru
Will Sangamo Therapeutics Inc. stock reach Wall Street targets2026 world cup usa national team final top scorers possession football expert forecast preview - Улправда
Sangamo Therapeutics (HAM:GBY) 9-Day RSI : 29.67 (As of Jan. 05, 2026) - GuruFocus
Q3 2025 Sangamo Therapeutics Inc Earnings Call Transcript - GuruFocus
Sangamo Therapeutics Inc at Evercore ISI HealthCONx Conference (Virtual) Transcript - GuruFocus
Sangamo Therapeutics (HAM:GBY) Preferred Stock - GuruFocus
Sangamo Therapeutics Inc (HAM:GBY) DCF Valuation - GuruFocus
Sangamo Therapeutics Inc Stock Baskets - GuruFocus
Sangamo Therapeutics (HAM:GBY) Intrinsic Value: Projected F - GuruFocus
Sangamo rises after trial data for Fabry disease therapy - MSN
H.C. Wainwright Maintains Buy Rating on Sangamo Therapeutics (SGMO) - MSN
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates - sharewise.com
Sangamo Therapeutics Stock Jump Looks Great, But How Secure Is That Gain? - Trefis
Why Sangamo Therapeutics Inc. stock could outperform in 2025Oil Prices & High Return Trade Guides - Улправда
Revenue Check: Can Sangamo Therapeutics Inc. stock surprise with earnings upsideJobs Report & Expert Approved Momentum Ideas - moha.gov.vn
Sangamo Starts Putting BLA for Fabry Disease Gene Therapy Isa-Vec in Front of FDA - CGTLive®
Growth Value: How Sangamo Therapeutics Inc. stock trades before earningsJuly 2025 PostEarnings & High Conviction Buy Zone Alerts - Улправда
How Sangamo Therapeutics Inc. stock trades before earningsJuly 2025 Gainers & Weekly Consistent Profit Watchlists - Улправда
Sangamo initiates rolling BLA submission for Fabry disease gene therapy By Investing.com - Investing.com Nigeria
Sangamo Therapeutics initiates rolling submission of BLA to U.S. FDA - marketscreener.com
Sangamo (SGMO) Begins BLA Submission for Promising Fabry Disease Therapy - GuruFocus
Sangamo initiates rolling BLA submission for Fabry disease gene therapy - Investing.com India
Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease - The Manila Times
Single-dose gene therapy for rare Fabry disease moves toward FDA review - Stock Titan
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Average Rating of "Hold" by Analysts - MarketBeat
Sangamo Therapeutics Earnings Notes - Trefis
Sangamo reports positive Fabry disease gene therapy results - MSN
How the Narrative Surrounding Sangamo Therapeutics Is Shifting After New Regulatory and Valuation Signals - Yahoo Finance
Book value per share of Sangamo Therapeutics, Inc. – SWB:GBY - TradingView — Track All Markets
Inflation Data: Is Sangamo Therapeutics Inc stock positioned well for digital economy2025 Breakouts & Breakdowns & Long Hold Capital Preservation Tips - moha.gov.vn
Sangamo receives U.S. FDA Fast Track Designation to ST-503 - MSN
Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber NeuropathyLife Science Industry News - Zenopa
Is Sangamo Therapeutics Stock Built to Withstand a Pullback? - Trefis
Sangamo rises as FDA grants Fast Track status to neuropathic pain asset - MSN
Why analysts recommend Sangamo Therapeutics Inc. (GBY) stockQuarterly Earnings Summary & Precise Buy Zone Identification - Newser
Sangamo Therapeutics Inc (SGMO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):